알림·소식
알림·소식
[2019 Pasteur Colloquium] Tatsuo Ido 박사, 가천대 뇌과학연구원
2019-08-23
____________________________________________
[한국파스퇴르연구소] 파스퇴르 콜로퀴엄
일시 : 2019년 8월 28일 (수), 오전 11시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
연자
Tatsuo Ido 박사
가천대 뇌과학연구원 Theragnostic Compound R&D Center 디렉터
강연주제
Development of PET radiopharmaceuticals and its application to Boron Neutron Capture Therapy
___________________________________________
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php
[한국파스퇴르연구소] 파스퇴르 콜로퀴엄
일시 : 2019년 8월 28일 (수), 오전 11시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
연자Tatsuo Ido 박사
가천대 뇌과학연구원 Theragnostic Compound R&D Center 디렉터
강연주제
Development of PET radiopharmaceuticals and its application to Boron Neutron Capture Therapy
초록
PET (Positron Emission Tomography) is one of the most effective methodologies for the functional and molecular imaging with high sensitivity and high quantitative measurement. This consists from the coincident matrix detection technique and the in-vivo positron tracer.
PET (Positron Emission Tomography) is one of the most effective methodologies for the functional and molecular imaging with high sensitivity and high quantitative measurement. This consists from the coincident matrix detection technique and the in-vivo positron tracer.
In 1976, first brain regional glucose consumption mapping in human had been succeeded with 18FDG in collaboration among of BNL NIH and Pen-Univ. These regional glucose consumption mapping had led to understanding of the function of central nerves system (specially, sensor cortex and motor cortex). 18FDG is also widely used for PET diagnosis of various tumor based on the tracer study of energy metabolism.
In 1982, the first neuro-receptor imaging (Dopamine D2) of human brain in-vivo with 11C-methylspiperon was succeeded in the collaborative work between Johns Hopkins Medical School and Uppsala University. This was the starting point of the molecular imaging by PET. After this, the compounds rerated to signal transduction (agonist, antagonist) were labelled with 11C or 18F and applied to determine synapse activity.
Recent highlight works in Brain PET research are the imaging of amyloidal plaque and active tau protein for Alzheimer Disease patient. 11C- and 18F-labelled thioflavin analogs have been developed as amyloidal plaque marker. Active tau protein image by 18F-THK compound (quinoline derivative) is closer related to cell denature than the amyloidal plaque image.
Another highlight work is the imaging of neuro-inflammation that may be important to find tissue denature at early stages in Parkinson Diseases, Alzheimer Disease and other neurodegenerative diseases. For this purpose, TSPO (translocator protein) ligand (phenoxyphenyl acetamide and oxo-purine derivatives) is labelled with 11C and 18F.
Also challenging application of PET to BNCT(cancer treatment) is progress to estimate the boron(10B) concentration in the target tumor.
In 1982, the first neuro-receptor imaging (Dopamine D2) of human brain in-vivo with 11C-methylspiperon was succeeded in the collaborative work between Johns Hopkins Medical School and Uppsala University. This was the starting point of the molecular imaging by PET. After this, the compounds rerated to signal transduction (agonist, antagonist) were labelled with 11C or 18F and applied to determine synapse activity.
Recent highlight works in Brain PET research are the imaging of amyloidal plaque and active tau protein for Alzheimer Disease patient. 11C- and 18F-labelled thioflavin analogs have been developed as amyloidal plaque marker. Active tau protein image by 18F-THK compound (quinoline derivative) is closer related to cell denature than the amyloidal plaque image.
Another highlight work is the imaging of neuro-inflammation that may be important to find tissue denature at early stages in Parkinson Diseases, Alzheimer Disease and other neurodegenerative diseases. For this purpose, TSPO (translocator protein) ligand (phenoxyphenyl acetamide and oxo-purine derivatives) is labelled with 11C and 18F.
Also challenging application of PET to BNCT(cancer treatment) is progress to estimate the boron(10B) concentration in the target tumor.
___________________________________________
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php